trending Market Intelligence /marketintelligence/en/news-insights/trending/TfuSD8XJsP7LDvqvPWN4JQ2 content esgSubNav
In This List

Lexicon's oral diabetes drug meets primary endpoint in phase 3 study

Blog

Insight Weekly: M&A outlook; US community bank margins; green hydrogen players' EU expansion

Blog

Global M&A by the Numbers: Q2 2022

Blog

Insight Weekly: US bank M&A; low refinancing eases rates impact; Texas crypto mining booms

Blog

Infographic 2022 Top Tech Trends Shaping Corporations


Lexicon's oral diabetes drug meets primary endpoint in phase 3 study

Lexicon Pharmaceuticals Inc.'s investigational, oral diabetes drug sotagliflozin met its primary endpoint in a phase 3 clinical trial.

The company was studying the treatment in type 1 diabetes patients who were on insulin therapy. The study met its primary endpoint after demonstrating superiority over placebo and a well-tolerated safety profile during a 24-week treatment period.

Results from the study will be submitted for publication in a peer-reviewed journal.

The drug is also being studied in adults with type 2 diabetes.